Skip to main content

Clinical Markers Improve With IV Ertapenem for Hidradenitis Suppurativa

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 21, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 21, 2024 -- Treatment of hidradenitis suppurativa (HS) with intravenous ertapenem is associated with improvement in clinical and inflammatory markers, according to a study published online Feb. 19 in JAMA Dermatology.

Avigdor Nosrati, M.D., from the Albert Einstein College of Medicine in New York City, and colleagues conducted a retrospective review of the medical records of 98 patients with HS between 2018 and 2022 to examine optimal course duration, efficacy, and patient satisfaction associated with intravenous ertapenem. Treatment was with 1 g of ertapenem, which was self-administered at home for 12 to 16 weeks.

The mean treatment duration spanned 13.1 weeks; posttherapy follow-up occurred after 7.8 weeks. The researchers observed significant reductions in the mean HS Physician Global Assessment scores from baseline to posttherapy follow-up and in the numerical rating scale for pain, C-reactive protein, interleukin-6, and leukocytes. Overall, 78.0 percent of the patients participated in the telephone survey at follow-up, with 80.3 percent reporting medium-to-high satisfaction. Most patients (90.8 percent) would recommend ertapenem to other patients.

"Larger, prospective, randomized clinical trials are needed to further optimize ertapenem dosing and duration, to evaluate the coadministration of other therapies, and to develop strategies for maintaining therapeutic outcomes," the authors write.

One author disclosed ties to Verrica Pharmaceuticals.

Abstract/Full Text (subscription or payment may be required)

Editor's Note (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

Factors ID'd That Affect Medical Decision-Making in Hidradenitis Suppurativa

WEDNESDAY, Jan. 17, 2024 -- Factors that affect medical decision-making among patients with hidradenitis suppurativa (HS) include suffering threshold, perceptions of treatment...

Crohn Disease More Common in People With Hidradenitis Suppurativa

WEDNESDAY, June 14, 2023 -- Pediatric patients with hidradenitis suppurativa (HS) have a higher prevalence of Crohn disease, according to a research letter published online June...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.